This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

BioForm Reports Smaller Fiscal 4Q Loss Of $1.9M

SAN MATEO, Calif. (AP) ¿ BioForm Medical Inc., which develops products used in cosmetic medical procedures, said Wednesday it shrank its fiscal fourth-quarter loss, due to improved sales and decreased operating expenses.

The company reported a loss of $1.9 million, or 4 cents per share, compared with a loss of $20 million, or 43 cents per share, in the same quarter last year. Revenue for the quarter that ended June 30 rose 15 percent to $19.2 million.

Analysts polled by Thomson Reuters expected a wider loss of 10 cents per share on $15.2 million in revenue.

BioForm said domestic sales rose 17 percent to $15.5 million, while international sales were up 6 percent to $3.7 million.

The company also said operating expenses fell more than 50 percent to $16.5 million.

It attributed most of the decrease to an $11.2 million charge taken in the fourth quarter last year that was tied to its Advanced Cosmetic Intervention asset purchase.

For the fiscal year that ended June 30, BioForm reported a loss of $21.1 million, or 46 cents per share, compared with a loss of $29.5 million, or 94 cents per share. Sales fell to $66.5 million from $67.5 million.

For fiscal 2010, BioForm expects a loss of less than $14 million and revenue of between $64 million and $70 million. Wall Street is looking for 2010 revenue of $66.4 million.

Shares added 19 cents, or 5.7 percent, to $3.53 in aftermarket trading, having closed the regular session at $3.34.
Copyright 2009 Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $117.82 -0.18%
FB $105.47 0.06%
GOOG $750.27 0.28%
TSLA $231.11 0.64%
YHOO $32.95 -0.63%


Chart of I:DJI
DOW 17,798.49 -14.90 -0.08%
S&P 500 2,090.11 +1.24 0.06%
NASDAQ 5,127.5250 +11.3820 0.22%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs